<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546442</url>
  </required_header>
  <id_info>
    <org_study_id>2005-02446-19</org_study_id>
    <nct_id>NCT00546442</nct_id>
  </id_info>
  <brief_title>Treatment Insulin Resistence in HCV G-1 Patient</brief_title>
  <acronym>TRIC-1</acronym>
  <official_title>Effect of Treatment of Insulin Resistance in Patients With Chronic Hepatitis C Genotype 1 Treated With Peginterferon Alfa-2a in Combination With Ribavirin in Current Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valme University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valme University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect of treatment of insulin resistance in the response of chronic&#xD;
      hepatitis C treatment, mesure as HCV-RNA negative at week 72.&#xD;
&#xD;
      4.3.2 Objetivos secundarios To evaluate the efficacy and safety of treatment with metformine&#xD;
      to erradicate the insulin resistance of patients with chornic hepatitis C genotype 1 measure&#xD;
      as HOMA-IR &lt; 2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Differents studies show that infection by virus hepatitis C have a relevant rol in the&#xD;
      development of insulin resistance. The insulin resistence is associated with a progression of&#xD;
      fibrosis and the development of steatosis. The insulin resistence is frecuently associated&#xD;
      with very difficult to cure patients as cirrhotics, afro-american patients, overweight&#xD;
      patients and co-infected HCV-HIV patients. Recently is repported that sustained virological&#xD;
      (SVR) response in genotype 1 patients is different according the insulin resistance. The SVR&#xD;
      was 60% in patients without insulin resistance versus 20% in patients with strong insulin&#xD;
      resistance (HOMA &gt; 4.&#xD;
&#xD;
      The present trial desire to analyze the effect that the treatment of insulin resistance&#xD;
      produce in higher range of RVS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with HCV-RNA</measure>
    <time_frame>Week 72</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who has erradicated the insulin resistance</measure>
    <time_frame>week 72</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of metformine 850-2550 mg/daily for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformine 850-2550 mg/daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformine</intervention_name>
    <description>850-2550 mg/daily for 48 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo of metformine</intervention_name>
    <description>850-2550 mg/daily for 48 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients with 18 years of age or more&#xD;
&#xD;
          -  Serum HCV-RNA quantifiable&#xD;
&#xD;
          -  Genotype 1&#xD;
&#xD;
          -  Liver disease compensated&#xD;
&#xD;
          -  HOMA-IR &gt; 2&#xD;
&#xD;
          -  Treatment with Peginterferon alfa-2a + Ribavirin.&#xD;
&#xD;
          -  Negative urine or blood pregnancy test (for women of childbearing potential)&#xD;
&#xD;
          -  All fertile males and females must be using effective contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Liver chirrosis&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Women with ongoing pregnancy or breast feeding&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Patients who during 6 months previous to treatment loss more of 10% of weight&#xD;
&#xD;
          -  Therapy with anti-neoplasic or immunomodulatory treatment (including supraphysiologic&#xD;
             doses of steroids and radiation) 6 months prior to the first dose of study drug&#xD;
&#xD;
          -  Any investigational drug 6 weeks prior to the first dose of study drug&#xD;
&#xD;
          -  History or other evidence of a medical condition associated with chronic liver disease&#xD;
             other than HCV&#xD;
&#xD;
          -  Carcinoma hepatocellular&#xD;
&#xD;
          -  History or other evidence of bleeding from esophageal varices or other conditions&#xD;
             consistent with decompensated liver disease&#xD;
&#xD;
          -  Neutrophil count &lt;1500 cells/mm3 or platelet count &lt;90,000 cells/mm3 at screening&#xD;
&#xD;
          -  Hgb &lt;12 g/dL in women or &lt;13 g/dL in men or any patient for whom anemia would be&#xD;
             medically problematic&#xD;
&#xD;
          -  History of significant cardiac disease that could be worsened by acute anemia&#xD;
&#xD;
          -  Serum creatinine level &gt;1.5 times the upper limit of normal at screening&#xD;
&#xD;
          -  History of severe psychiatric disease, especially depression. Severe psychiatric&#xD;
             disease is defined as treatment with an antidepressant medication or a major&#xD;
             tranquilizer at therapeutic doses for major depression or psychosis, respectively, for&#xD;
             at least 3 months at any previous time or any history of the following: a suicidal&#xD;
             attempt, hospitalization for psychiatric disease, or a period of disability due to a&#xD;
             psychiatric disease&#xD;
&#xD;
          -  History of a severe seizure disorder or current anticonvulsant use&#xD;
&#xD;
          -  History of immunologically mediated disease, chronic pulmonary disease associated with&#xD;
             functional limitation, severe cardiac disease, major organ transplantation or other&#xD;
             evidence of severe illness, malignancy, or any other conditions which would make the&#xD;
             patient, in the opinion of the investigator, unsuitable for the study&#xD;
&#xD;
          -  History of thyroid disease poorly controlled on prescribed medications, elevated&#xD;
             thyroid stimulating hormone (TSH) concentrations with elevation of antibodies to&#xD;
             thyroid peroxidase and any clinical manifestations of thyroid disease&#xD;
&#xD;
          -  Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration)&#xD;
&#xD;
          -  Evidence of drug abuse (including excessive alcohol consumption) within one year of&#xD;
             study entry&#xD;
&#xD;
          -  Inability or unwillingness to provide informed consent or abide by the requirements of&#xD;
             the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manuel Romero-Gomez, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario de Valme. Sevilla</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Donostia</name>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital de Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario San Cecilio</name>
      <address>
        <city>Granada</city>
        <zip>18003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Leon</name>
      <address>
        <city>Leon</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos III</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <zip>28035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>October 17, 2007</study_first_submitted>
  <study_first_submitted_qc>October 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <last_update_submitted>October 17, 2007</last_update_submitted>
  <last_update_submitted_qc>October 17, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2007</last_update_posted>
  <keyword>insulin resistance</keyword>
  <keyword>chronic hepatitis C</keyword>
  <keyword>genotype 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

